Avexegen Therapeutics Competitors and Similar CompaniesClear all
Avexegen Therapeutics's competitors and similar companies include Travere Therapeutics, GBT (Global Blood Therapeutics), Xcelthera and Antiva Biosciences.
 Avexegen Therapeutics Avexegen Therapeutics is a biotechnology company developing therapies for patients with gastrointestinal disorders. |  Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. |  Xcelthera Xcelthera is a biopharmaceutical company developing a stem cell therapy for a range of neurological and cardiovascular diseases. |  Antiva Biosciences Antiva Biosciences is a biopharmaceutical company which develops therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection. | |
Founding Date | Founding Date 2014 | Founding Date 2011 | Founding Date 2012 | Founding Date 2013 | Founding Date 2012 |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations San Diego, US HQ Dublin, IE | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB | Locations HQ | Locations South San Francisco, US HQ Redwood City, US |
Employees | Employees 6 | Employees 46293% increase | Employees 352106% increase | Employees 2 | Employees N/A |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) 4.4 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $490.7m (FY, 2025) | Revenue (est.) $194.7m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $10.3m (FY, 2025) | Cost of goods $3.3m (FY, 2021) | Cost of goods N/A | Cost of goods N/A |
Net income | Net income N/A | Net income ($25.5m) (FY, 2025) | Net income ($303.1m) (FY, 2021) | Net income N/A | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 25m | Total funding raised $ 88.7m | Total funding raised N/A | Total funding raised $ 56.4m |
For sources of this data, please see the company profile
View Company Profiles
Travere Therapeutics
HQ
San Diego, US
Employees
462
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View companyXcelthera
HQ
Employees
2
Xcelthera is a biopharmaceutical company developing a stem cell therapy for a range of neurological and cardiovascular diseases.
View companyAntiva Biosciences
HQ
South San Francisco, US
Antiva Biosciences is a biopharmaceutical company which develops therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection.
View company